Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 18, 2021

FDA grants marketing authorisation to BioFire’s SARS-CoV-2 diagnostic test

The US Food and Drug Administration (FDA) has granted marketing authorisation to BioFire Diagnostics’ SARS-CoV-2 test.

The US Food and Drug Administration (FDA) has granted marketing authorisation to BioFire Diagnostics’ SARS-CoV-2 test.

The BioFire Respiratory Panel 2.1 (RP2.1) diagnostic test secured a marketing permit for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from people suspected of Covid-19 and other infections related to the respiratory tract.

FDA granted the permit under the De Novo premarket review pathway, a regulatory pathway to review new type of low- to moderate-risk devices.

The new test is claimed to be the first SARS-CoV-2 diagnostic test that will be permitted to be marketed beyond the public health emergency.

FDA acting commissioner Janet Woodcock said: “Today’s action is a great demonstration of the FDA’s work to protect the public health in emergency response situations and beyond.

“We ensured there were tests made available quickly under EUA, and we continue to work with diagnostic manufacturers to take the next step of ensuring products are FDA reviewed for safety and effectiveness and authorised for marketing under our traditional premarket authorities.”

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The De Novo request for this test was granted based on additional data that showed validation beyond what is needed for Emergency Use Authorization (EUA).

The FDA also reviewed data from a clinical study of more than 500 test samples and various analytical studies.

As the new test has been authorised through a traditional premarket review pathway, the FDA has revoked the EUA for this device that was initially authorised in May.

However, the FDA stated that the EUA revocation and De Novo authorisation ‘do not impact the availability of other tests under EUA’.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU